Sanofi Drops 3.37% Amid Leadership Shakeup, FDA Designation

On April 7, 2025, Sanofi's stock dropped by 3.37% in pre-market trading.

Sanofi has recently appointed Feng Ji as the new CEO and Chief Operating Officer, replacing Dai Hongbin who has been promoted to Vice Chairman. Feng Ji brings over 20 years of experience in the pharmaceutical industry, having previously held senior positions at AstraZeneca, Novartis, and Amgen. This leadership change is expected to bring a fresh perspective and strategic direction to Sanofi's operations.

Additionally, Sanofi's pipeline candidate, rilzabrutinib, has received orphan drug designation from the FDA for the treatment of two rare diseases, warm autoimmune hemolytic anemia and IgG4-related disease. This designation is a significant milestone for Sanofi, as it provides incentives for the development of treatments for rare diseases.